Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Rivoceranib

Generic Name: Rivoceranib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Overview

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication

本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase 2

Withdrawn

Posted: 2024/03/13

Sponsor:M.D. Anderson Cancer...

ID:NCT06308575

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Phase 2

Recruiting

Posted: 2024/03/06

Sponsor:

Lei ZHAO

ID:NCT06296563

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Posted: 2024/02/28

Sponsor:

Sun Yat-sen Universi...

ID:NCT06281886

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3

Not yet recruiting

Posted: 2024/02/13

Sponsor:Sun Yat-Sen Memorial...

ID:NCT06255392

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC

Phase 2

Completed

Posted: 2024/02/02

Sponsor:Renmin Hospital of W...

ID:NCT06238752

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

HAIC with FOLFOX Plus Camrelizumab and Sorafenib Shows Limited Efficacy in Advanced HCC

14 days ago

A phase II trial investigating hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib in BCLC stage C hepatocellular carcinoma failed to meet its primary endpoint, showing a modest 44% objective response rate.

Innovent Biologics to Present Breakthrough Clinical Data for IBI363 PD-1/IL-2 Bispecific Antibody at ASCO 2025

a month ago

Innovent Biologics will showcase seven oral presentations at ASCO 2025, featuring breakthrough clinical data for its novel PD-1/IL-2α-bias bispecific antibody IBI363 in melanoma, colorectal cancer, and non-small cell lung cancer.

FDA Issues Second Rejection for Rivoceranib/Camrelizumab Combination in Unresectable Liver Cancer

2 months ago

The FDA has issued a second Complete Response Letter (CRL) for the rivoceranib/camrelizumab combination therapy for unresectable hepatocellular carcinoma, with no specific reasons disclosed for the rejection.

Robust Pipeline for Nasopharyngeal Cancer Treatment Emerges with 25+ Pharmaceutical Companies Developing Novel Therapies

3 months ago

A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing approximately 30 drug candidates for nasopharyngeal cancer, signaling significant industry investment in this therapeutic area.

ESMO Endorses HLB's CAM-RIVO for First-Line Liver Cancer Treatment Ahead of FDA Decision

3 months ago

HLB's combination therapy CAM-RIVO has been added to ESMO guidelines as a first-line treatment for hepatocellular carcinoma, receiving a "very strong" clinical evidence rating.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy